• Bitcoin-1,521.25
    $11,459.75-12.97%
    $175,016,158,112.00
  • Ethereum-109.12
    $952.98-11.45%
    $92,587,551,437.00
  • Exchange Union-0.33
    $8.16-4.02%
    $16,322,520.00
  • Ripple-0.14
    $1.25-11.05%
    $48,231,782,365.00
  • Veritaseum-46.70
    $337.46-13.84%
    $687,292,480.00
  • Digitalcoin-0.01
    $0.07-14.89%
    $1,986,979.00
  • Bitcoin-1,521.25
    $11,459.75-12.97%
    $175,016,158,112.00
  • Ethereum-109.12
    $952.98-11.45%
    $92,587,551,437.00
  • Exchange Union-0.33
    $8.16-4.02%
    $16,322,520.00
  • Ripple-0.14
    $1.25-11.05%
    $48,231,782,365.00
  • Veritaseum-46.70
    $337.46-13.84%
    $687,292,480.00
  • Digitalcoin-0.01
    $0.07-14.89%
    $1,986,979.00
 
detail
HEADING -BIG BOLD FONT FOR I PHONE IMAGE COLUMS

This is a wider card with supporting text below as a natural lead-in to additional content. This content is a little bit longer.

post

OCT 04, 2019, 18:00 ETNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg

 
 
detail
HEADING -BIG BOLD FONT FOR I PHONE IMAGE COLUMS

This is a wider card with supporting text below as a natural lead-in to additional content. This content is a little bit longer.

detail
HEADING -BIG BOLD FONT FOR I PHONE IMAGE COLUMS

This is a wider card with supporting text below as a natural lead-in to additional content. This content is a little bit longer.

detail
HEADING -BIG BOLD FONT FOR I PHONE IMAGE COLUMS

This is a wider card with supporting text below as a natural lead-in to additional content. This content is a little bit longer.

post

OCT 04, 2019, 18:00 ETNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg

post

OCT 04, 2019, 18:00 ETNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg

post

OCT 04, 2019, 18:00 ETNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

detail
HEADING -BIG BOLD FONT FOR I PHONE IMAGE COLUMS

This is a wider card with supporting text below as a natural lead-in to additional content. This content is a little bit longer.

detail
HEADING -BIG BOLD FONT FOR I PHONE IMAGE COLUMS

This is a wider card with supporting text below as a natural lead-in to additional content. This content is a little bit longer.

detail
HEADING -BIG BOLD FONT FOR I PHONE IMAGE COLUMS

This is a wider card with supporting text below as a natural lead-in to additional content. This content is a little bit longer.

post

OCT 04, 2019, 18:00 ETNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg

post

OCT 04, 2019, 18:00 ETNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg

post

OCT 04, 2019, 18:00 ETNeurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress